Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
Haveli closes debut $4.5bn software buyout fund led by Vista co-founder Brian Sheth
Haveli closes debut $4.5bn software buyout fund led by Vista co-founder Brian Sheth Haveli Investments has raised $4.5bn for its first software buyout fund, marking a major milestone for the private equity firm founded by Vista Equity Partners co-founder Brian Sheth,...
Calpers deepens private equity exposure after strong $556.2bn performance year
Calpers deepens private equity exposure after strong $556.2bn performance year Calpers is expanding its private equity portfolio following its strongest fiscal year since 2021, reporting an 11.6% return and reaching $556.2bn in total assets under management, according...
Bain Capital and Kohlberg back $10bn PCI Pharma in latest biopharma bet
Bain Capital and Kohlberg back $10bn PCI Pharma in latest biopharma bet Bain Capital and Kohlberg are leading a new multibillion-dollar investment in PCI Pharma Services, valuing the Philadelphia-based biopharma outsourcing company at $10bn, including debt, according...